Patent · US Active

High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof

US11207342B2 · kind B2 · utility

0Cited by

0References

25Claims

0Family size

Assignees

Alnylam Pharmaceuticals, Inc. · US
ETH ZURICH · CH

Inventors

Muthiah Manoharan · Carlsbad, US
Markus Stoffel · Herrliberg, CH
Mehrpouya Balaghy Mobin · Cologne, DE

Key dates

Filing date	Oct 17, 2018
Grant date	Dec 28, 2021
Priority date	—
Expiry date	Feb 2, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3533
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.